Xbiome has acquired 1 company, including 1 in the last 5 years.
Xbiome has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2022-04-25 |
Assembly Biosciences - Clinical-Stage M201 Program · Life Science
San Francisco, California Assembly Biosciences' Clinical-Stage M201 Program is designed for patients with mild to moderate ulcerative colitis. M201 is comprised of a rationally designed consortium of commensal bacteria that were selected based on their ability to modulate ulcerative colitis-relevant cellular mechanisms in human cell-based assays and animal models. |
- | Divestiture |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
